SLC5A2 and type 2 diabetes mellitus: Beyond cardiac and kidney benefits, in people with type 2 diabetes and metabolic-associated steatotic liver disease a network meta-analysis indicated that each one of GLP-1 receptor agonists and SGLT-2 inhibitors have a favourable effect on liver steatosis [42], thereby paving the way for evaluating combination regimens for this indication.